Medical Marijuana, Inc. HempMeds Brasil Subsidiary Celebrates Forbes Article

Medical Marijuana, Inc.


HempMeds Brasil in Forbes

HempMeds Brasil in Forbes

SAN DIEGO, Calif., May 23, 2022 (GLOBE NEWSWIRE) — via NewMediaWire Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chains, announced today today that its subsidiary HempMeds® Brazil was featured in Forbes on his recent successes.

The article titled “The Stages of Cannabis in Brazil” details how HempMeds® Brasil has grown 50% year-on-year since its inception in 2014 and how the company has collaborated in importing over 140,000 cannabis-derived products for Brazilian citizens.

“We are thrilled to have had the opportunity to share our message with the public and continue to reach more customers every day,” said Matheus Patelli, Executive Director of HempMeds® Brasil. “Articles like this are great for the cannabis industry because they help raise awareness of companies that are doing great things to contribute to people’s health and well-being and help reduce product stigma. cannabis-based.”

It is also important to note that in the first quarter of 2022, HempMeds® Brasil grew 75.8% faster than the overall cannabidiol (CBD) market. This milestone can be attributed to the subsidiary’s extensive network of doctors and healthcare professionals and the reliability of its high-quality CBD products.

“It’s incredibly rewarding to see our business activity in Brazil grow and get the attention it deserves,” said Medical Marijuana, Inc. CEO Blake Schroeder. “Brazil has played an important role in our international expansion and we are proud of the legacy of free access we have created in Brazil and around the world, which has impacted lives and brought about positive global change. “

To learn more about HempMeds® Brasil, please visit

About HempMeds® Brazil
HempMeds® Brasil was the first company to receive approval from the National Health Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help control diseases such as epilepsy, Parkinson’s disease, chronic pain and multiple sclerosis, under medical prescription. For these indications, products may be subsidized by the Brazilian government. HempMeds® Brasil is working on additional approvals for other indications.

About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct non-psychoactive cannabinoid business units: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in providing the highest quality non-psychoactive legal cannabis products derived from industrial hemp; and a clinical research and development sector for cannabinoid-based botanical drugs led by its pharmaceutical investment companies and partners, including AXIM® Biotechnologies, Inc.. and Neuropathix. Medical Marijuana, Inc. was named one of the top CBD producers by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in developing international markets. The company’s flagship product Genuine Scientific Hemp Oil has been used in several successful clinical studies in Mexico and Brazil to understand its safety and effectiveness.

Medical Marijuana, Inc. is headquartered in San Diego, CA and additional information is available at or by visiting To view the Medical Marijuana, Inc. corporate video, Click here.

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by these articles. This document contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. These forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ materially from the statements made herein.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Medical Marijuana, Inc. does not sell or distribute products that violate the US Controlled Substances Act.

Public relations contact:
Katherine Brown
Account director
CMW Media
[email protected]

Contact with Investor Relations:
T. (858) 283-4016
[email protected]


About Warren Dockery

Check Also

As China plays down Tangshan aggression, women say their rights are under attack

Placeholder while loading article actions When a mother was found chained in a shed in …